New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 2, 2013
07:08 EDTCLDXCelldex initiates accelerated approval study of Glembatumumab vedotin
Celldex Therapeutics announced that it has launched a randomized study of Glembatumumab vedotin in patients with metastatic triple negative breast cancers that over-express glycoprotein NMB, or gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a specific protein that is expressed in breast cancer which promotes the migration, invasion and metastasis of the disease. It is also highly expressed in triple negative breast cancers where it is associated with increased risk of recurrence. Initial sites are now open to screen patients in the United States. Additional sites in the United States and in Canada and Australia will open in early 2014. The study is expected to include up to 100 sites and will enroll approximately 300 patients.
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
14:02 EDTCLDXCelldex Phase 1 study of CDX-1401 demonstrates robust antibody response
Subscribe for More Information
April 15, 2014
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 7, 2014
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.
April 4, 2014
09:50 EDTCLDXCelldex management to meet with Guggenheim
Meetings to be held in New York on April 10-11 hosted by Guggenheim.
April 3, 2014
08:27 EDTCLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
08:11 EDTCLDXCelldex to present CDX-014 preclinical proof of concept data at AACR
Celldex Therapeutics announced that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate CDX-014 will be presented at the American Association of Cancer Research, or AACR, Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1, which is upregulated in several cancers, including renal and ovarian carcinomas.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use